Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Chang, Cheng Chang ^a,b   Huang, Rui Lan ^c   Liao, Yu Ping ^b   Su, Po Hsuan ^b   Hsu, Yaw Wen ^b   Wang, Hui Chen ^b   Tien, Chau Yang ^a   Yu, Mu Hsien ^a   Lin, Ya Wen ^b   Lai, Hung Cheng ^b,c,d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Biomarker; Cervical cancer; DNA methylation; Physician collected; Real time quantitative methylation specific polymerase chain reaction (QMSP); Self collected

Indexed keywords

BIOLOGICAL MARKER; PAIRED BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX1; TUMOR MARKER;

ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DNA METHYLATION; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; PAX1 GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SOX1 GENE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; ZNF582 GENE; CANCER STAGING; CARCINOMA IN SITU; EARLY CANCER DIAGNOSIS; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; REFERENCE VALUE; REPRODUCIBILITY; VAGINA SMEAR;

ADULT; BIOMARKERS, TUMOR; CARCINOMA IN SITU; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA METHYLATION; EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; ROC CURVE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84930201291     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1411-x     Document Type: Article

References (37)

1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461-84.
2. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364:249-56.
3. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer. 2006;119:2372-5.
4. de Bie RP, Vergers-Spooren HC, Massuger LF, Siebers AG, der Pol MR S-v, Vedder JE, et al. Patients with cervical cancer: why did screening not prevent these cases? Am J Obstet Gynecol. 2011;205(64):e61-7.
5. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-50.
6. Bosgraaf RP, Verhoef VM, Massuger LF, Siebers AG, Bulten J, de Kuyper-de Ridder GM, et al. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int J Cancer J Int du cancer. 2014;136:646-55.
7. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmeron J, Uribe P, Velasco-Mondragon E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011;378:1868-73.
8. Virtanen A, Nieminen P, Luostarinen T, Anttila A. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev. 2011;20:1960-9.
9. Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J Natl Cancer Inst. 2012;104:178-88.
10. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer. 2011;104:915-20.
11. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer. 2013;132:2223-36.
12. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-101.
13. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78-88.
14. Garcia F, Barker B, Santos C, Brown EM, Nuno T, Giuliano A, et al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol. 2003;102:266-72.
15. Farkas SA, Milutin-Gasperov N, Grce M, Nilsson TK. Genome-wide DNA methylation assay reveals novel candidate biomarker genes in cervical cancer. Epigenetics. 2013;8:1213-25.
16. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112:293-9.
17. Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, et al. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer. 2010;116:4266-74.
18. Huang RL, Chang CC, Su PH, Chen YC, Liao YP, Wang HC, et al. Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582) in cervical neoplasms. PLoS One. 2012;7:e41060.
19. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:114-23.
20. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014;15:315-22.
21. Hesselink AT, Heideman DA, Steenbergen RD, Coupe VM, Overmeer RM, Rijkaart D, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res. 2011;17:2459-65.
22. Overmeer RM, Louwers JA, Meijer CJ, van Kemenade FJ, Hesselink AT, Daalmeijer NF, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer. 2011;129:2218-25.
23. Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, et al. A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One. 2014;9:e91905.
24. Eijsink JJ, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer. 2012;130:1861-9.
25. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008;123:161-7.
26. Chang CC, Huang RL, Wang HC, Liao YP, Yu MH, Lai HC. High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma. Int J Gynecol Cancer. 2014;24:201-9.
27. Lin H, Chen TC, Chang TC, Cheng YM, Chen CH, Chu TY, et al. Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions - a Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol Oncol. 2014;135:64-8.
28. Lai HC, Ou YC, Chen TC, Huang HJ, Cheng YM, Chen CH, et al. PAX1/SOX1 DNA methylation and cervical neoplasia detection: a Taiwanese Gynecologic Oncology Group (TGOG) study. Cancer medicine. 2014;3:1062-74.
29. Chu TY, Hwang KS, Yu MH, Lee HS, Lai HC, Liu JY. A research-based tumor tissue bank of gynecologic oncology: characteristics of nucleic acids extracted from normal and tumor tissues from different sites. Int J Gynecol Cancer. 2002;12:171-6.
30. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-5.
31. Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, et al. DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. Br J Cancer. 2014;111:1095-101.
32. Waller J, Jackowska M, Marlow L, Wardle J. Exploring age differences in reasons for nonattendance for cervical screening: a qualitative study. BJOG. 2012;119:26-32.
33. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-9.
34. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252-8.
35. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-92.
36. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study G: Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. Jama. 2001;285:1500-5.
37. Carreon JD, Sherman ME, Guillen D, Solomon D, Herrero R, Jeronimo J, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26:441-6.